Clinical significance of anti-Epstein–Barr virus antibodies in systemic chronic active Epstein–Barr virus disease
Miwako Nishio, Minori Saito, Mayumi Yoshimori, Yuki Kumaki, Ayaka Ohashi, Eri Susaki, Ichiro Yonese, Megumi Sawada, Ayako Arai · 2024
Read Clinical significance of anti-Epstein–Barr virus antibodies in systemic chronic active Epstein–Barr virus disease by Miwako Nishio, Minori Saito, Mayumi Yoshimori, Yuki Kumaki, Ayaka Ohashi, Eri Susaki, Ichiro Yonese, Megumi Sawada, Ayako Arai (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10800478.txt.
Description
Miwako Nishio and co-authors read antibody patterns in a rare, fatal disease where the Epstein-Barr virus infects the body's own killer cells. Their study appeared in 2023, though the catalog lists 2024. Using a Japanese nationwide survey, they analyzed 84 patients across childhood to old age. Antibodies against the virus's hidden nuclear protein appeared in most patients, but at lower levels than in healthy people. Antibodies against the virus's outer shell ran higher.
Patients with strong shell and early-protein antibody levels survived better at three years than those with weak ones. The authors read the pattern as a dulled immune aim at infected cells, partly compensated by anti-particle responses. They suggest antibody profiles could help predict the disease's course.
Catalog record
| CREATOR | Miwako Nishio, Minori Saito, Mayumi Yoshimori, Yuki Kumaki, Ayaka Ohashi, Eri Susaki, Ichiro Yonese, Megumi Sawada, Ayako Arai |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |